Equitable Holdings Inc. bought a new stake in Boston Scientific Corporation (NYSE:BSX - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 29,331 shares of the medical equipment provider's stock, valued at approximately $1,252,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Brasada Capital Management LP acquired a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $2,633,000. Coastal Bridge Advisors LLC acquired a new position in Boston Scientific during the second quarter valued at approximately $1,023,000. Public Employees Retirement System of Ohio acquired a new position in Boston Scientific during the second quarter valued at approximately $24,391,000. MASTERINVEST Kapitalanlage GmbH bought a new stake in Boston Scientific during the second quarter worth $2,822,000. Finally, Proficio Capital Partners LLC bought a new stake in Boston Scientific during the second quarter worth $434,000. Institutional investors own 89.07% of the company's stock.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on BSX. Wall Street Zen lowered Boston Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, August 2nd. Weiss Ratings downgraded Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, July 7th. Evercore set a $65.00 price objective on Boston Scientific in a research note on Monday, July 6th. Wolfe Research downgraded Boston Scientific from an "outperform" rating to a "peer perform" rating in a research note on Friday, May 29th. Finally, Argus reissued a "hold" rating on shares of Boston Scientific in a report on Friday, July 31st. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $71.62.
View Our Latest Stock Report on Boston Scientific
Boston Scientific Trading Up 0.3%
BSX opened at $46.82 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The company's 50 day moving average price is $46.56 and its two-hundred day moving average price is $56.65. The firm has a market capitalization of $67.85 billion, a price-to-earnings ratio of 18.96, a PEG ratio of 1.02 and a beta of 0.56.
Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company's revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.
Boston Scientific announced that its board has authorized a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board believes its stock is undervalued.
Insider Buying and Selling
In related news, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average cost of $45.48 per share, with a total value of $227,400.00. Following the transaction, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Michael F. Mahoney bought 186,240 shares of the business's stock in a transaction on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 194,522 shares of company stock valued at $9,385,210 in the last three months. Insiders own 0.34% of the company's stock.
Boston Scientific Profile
(
Free Report)
Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
